Strong Cross-Pillar

Cui Bono: Follow the Money Before You Trust the Claim

Name: Cui Bono: Follow the Money Before You Trust the Claim
Creator: Realised
Published: 2026-06-01

Summary

"Who profits if I believe this?" is a fast, powerful filter on any health claim — industry-funded studies reliably tilt toward their sponsor, usually through design and spin rather than fraud — and the rule has to be applied symmetrically: be just as skeptical of the supplement seller, the wellness influencer, and the "natural" brand as of Big Pharma. Funding doesn't make a claim false, but it tells you where to look hardest.

Why Strong

Tier 1 (Strong). The funding-effect and conflict-of-interest literature is large, replicated, and methodologically robust (Cochrane). It's a Strong, evidenced tool under the Foundational evidence-literacy hub. The symmetric application is an editorial principle built on that evidence.

Practical takeaway

• Ask "cui bono?" first — who profits if I believe this, buy this, fear this? Use it as a triage filter on every claim, headline, and recommendation.
• Find the funding and conflicts — check the funding statement and COI disclosures; note if the study's authors sell the product or method.
• Apply it symmetrically — the supplement/wellness/"natural" seller gets the same scrutiny as the drug company. A counter-narrative is also a product.
• Weight, don't dismiss — funded ≠ false. Independent replication, pre-registration, and hard outcomes (the hub + publication_bias_and_evidence_distortion) are what upgrade a conflicted finding.
• Prefer independent, replicated, pre-registered evidence when stakes are high; treat single sponsor-funded studies as leads, not conclusions.
• Watch for the tells — relative-risk-only framing, surrogate outcomes, no pre-registration, testimonials instead of trials, "disclosed so it's fine."

Evidence detail

Why This Entry Exists

Money shapes what gets studied, how, and how it's spun — and most people apply this insight selectively, distrusting one industry while swallowing another's marketing whole. The skeptic who rejects a pharma trial but believes a supplement influencer has simply swapped one sponsor for another. This entry makes the cui-bono lens explicit and symmetric, which is the core of Realised's editorial stance: follow the money in every direction. It's the spoke that turns "the evidence is biased" into an actionable question — biased by whom, toward what, and how?

It pairs tightly with publication_bias_and_evidence_distortion (funding is a major engine of that distortion) under the rct_vs_observational_evidence hub.

What bad thinking this protects against:
• "It's from a peer-reviewed, funded study, so it's neutral" → ignoring sponsor-favouring design and spin.
• "Big Pharma lies, but this natural brand / influencer is honest" → asymmetric skepticism that just trusts a different seller.
• "They disclosed the conflict, so it's fine" → disclosure ≠ neutrality.

Evidence

1. Industry funding predicts favourable conclusions (Tier 1). The Cochrane methodology review (Lundh et al., "Industry sponsorship and research outcome") found drug and device studies funded by manufacturers more often reach favourable efficacy conclusions and favourable spin than independently-funded studies — a robust, replicated finding. The mechanism is rarely outright fraud; it's choices.

2. The levers of bias, without lying (Tier 1):
• Comparator choice — test against placebo, or a too-low/too-high dose of a competitor, to look better.
• Outcome choice / surrogates — measure a marker that moves rather than the hard outcome (see surrogate reasoning in the hub).
• Selective publication & outcome-switching — bury negative trials, promote favourable ones (see publication_bias_and_evidence_distortion).
• Spin — frame a non-significant or small result positively in the abstract; quote relative risk (see relative_vs_absolute_risk).
• Ghostwriting / key-opinion-leaders — sponsor-shaped papers and paid expert advocacy.

3. It's not just pharma — the "natural"/wellness side has the same incentives (Tier 1). Supplement, "clean beauty," superfood, device, and influencer markets fund favourable studies, lean on mechanism/testimonial (cheaper than RCTs), and sell the counter-narrative (fear of the drug/chemical) as their product. Concrete cross-field example: a 2023 meta-analysis reporting weight loss from psyllium fibre was authored by Procter & Gamble employees (maker of Metamucil), while an independent meta-analysis found no weight effect — same nutrient, opposite conclusion, traceable to who ran it.

4. Even researchers can be vendors (Tier 1). Conflicts aren't only corporate. In the fascia field, the most-cited researcher is simultaneously a method-association director and a foam-roller-company expert, and the flagship conference is sponsored by a method's institute ("Identifying Conflicts of Interest in Therapeutic Massage and Bodywork Research") — so the data can be sound while the "therefore buy/do this" layer is sell-side.

5. Disclosure helps but doesn't neutralise (Tier 1). Conflict-of-interest disclosure improves transparency but does not remove the bias; disclosed conflicts still predict favourable findings. "They told us they're funded by X" is a reason to scrutinise, not to relax.

Mechanism

Why money bends findings without fraud. A sponsor doesn't need to falsify data; they shape the garden of forking paths — which question, which comparator, which dose, which outcome, which analysis, whether to publish, how to phrase the abstract. Each choice is individually defensible, but they aggregate toward the sponsor's interest. That's why funding source is a strong predictor of conclusions even in honestly-conducted studies.

Why symmetric application matters. Bias is about incentive, not corporate size. A solo influencer selling a course, a supplement brand, a wellness clinic, and a pharma company all have a stake in your belief. Distrusting only the largest or least-liked actor leaves you wide open to the others — which is exactly how "natural"/wellness marketing succeeds with otherwise-skeptical people.

RISKS AND CONTRAINDICATIONS (how this gets misused)

• Ad hominem / genetic fallacy — "it's industry-funded, therefore false." Funding is a flag to scrutinise, not a refutation; well-run sponsored RCTs can be correct.
• Conspiracy spiral — escalating from "incentives bias findings" to "it's all coordinated fraud," which discredits the real, mundane, structural point.
• Asymmetric weaponisation — invoking cui bono only against claims you dislike. The whole value is in applying it evenly, including to your own preferred sources.
• Dismissing necessary medicine — letting pharma-skepticism push someone away from genuinely effective, well-evidenced treatment.

Controversy

That funding biases research is not controversial — it's one of the best-replicated findings in meta-research (Lundh/Cochrane). The contested parts are how much in a given case and what to do about it (disclosure vs independent funding vs banning sponsored trials). Realised's stance is the symmetric one: follow the money everywhere, weight accordingly, and prefer independent/replicated/pre-registered evidence — without sliding into "all evidence is fake."

Cross-Pillar Connections

• Hub (rct_vs_observational_evidence): cui bono is the "who funded it / pre-registered?" question in the hub's checklist, expanded.
• publication_bias_and_evidence_distortion: funding is a primary engine of selective publication and spin.
• relative_vs_absolute_risk: the framing sponsors choose (relative, surrogate) is a cui-bono tell.
• belief_effects_and_honest_framing: testimonials/marketing exploit expectancy in place of evidence.

Industry bias note

Structural incentives the evidence base may reflect

This entry is the platform's bias-analysis principle itself, generalised. The point worth stating plainly: Realised applies cui bono to "natural," "wellness," and "clean" sellers exactly as hard as to pharma — because the wellness/supplement economy is a multi-billion-dollar industry that profits from fear of medicine and from un-trialled products, and it exploits people's (correct) distrust of pharma to sell the counter-narrative. The anchor is the independent meta-research community (Cochrane methodology, COI scholarship), which has no product to sell.

Sources (5)

Open in the Library: search, filter, every entry →